Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.2278
-0.0501 (-18.03%)
At close: Jan 30, 2026, 4:00 PM EST
0.2244
-0.0034 (-1.49%)
After-hours: Jan 30, 2026, 7:59 PM EST
Propanc Biopharma Employees
As of June 30, 2025, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$31,703,364
Market Cap
3.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2024 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2023 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 1 | 2 |
| Jun 30, 2021 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Lyra Therapeutics | 30 |
| Cardio Diagnostics Holdings | 15 |
| Ensysce Biosciences | 8 |
| Artelo Biosciences | 5 |
| CNS Pharmaceuticals | 5 |
PPCB News
- 5 days ago - Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - GlobeNewsWire
- 12 days ago - Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - GlobeNewsWire
- 17 days ago - Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - GlobeNewsWire
- 19 days ago - Propanc Biopharma Provides Shareholder Update - GlobeNewsWire
- 5 weeks ago - Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - GlobeNewsWire
- 2 months ago - Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - GlobeNewsWire
- 2 months ago - Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - GlobeNewsWire
- 2 months ago - Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results - GlobeNewsWire